Lu Ben, Wang Ce, Wang Mao, Li Wei, Chen Fangping, Tracey Kevin J, Wang Haichao
Department of Hematology, The 3rd Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China.
Expert Rev Clin Immunol. 2014 Jun;10(6):713-27. doi: 10.1586/1744666X.2014.909730. Epub 2014 Apr 19.
High mobility group box 1 (HMGB1) is an evolutionarily conserved protein, and is constitutively expressed in virtually all types of cells. Infection and injury converge on common inflammatory responses that are mediated by HMGB1 secreted from immunologically activated immune cells or passively released from pathologically damaged cells. Herein we review the emerging molecular mechanisms underlying the regulation of pathogen-associated molecular patterns (PAMPs)-induced HMGB1 secretion, and summarize many HMGB1-targeting therapeutic strategies for the treatment of infection- and injury-elicited inflammatory diseases. It may well be possible to develop strategies that specifically attenuate damage-associated molecular patterns (DAMPs)-mediated inflammatory responses without compromising the PAMPs-mediated innate immunity for the clinical management of infection- and injury-elicited inflammatory diseases.
高迁移率族蛋白B1（HMGB1）是一种进化上保守的蛋白质，几乎在所有类型的细胞中都有组成性表达。感染和损伤会引发共同的炎症反应，这些反应由免疫激活的免疫细胞分泌的HMGB1或病理损伤细胞被动释放的HMGB1介导。在此，我们综述了病原体相关分子模式（PAMPs）诱导HMGB1分泌调控的新出现的分子机制，并总结了许多针对HMGB1的治疗策略，用于治疗感染和损伤引发的炎症性疾病。很有可能开发出特异性减弱损伤相关分子模式（DAMPs）介导的炎症反应而不损害PAMPs介导的固有免疫的策略，用于感染和损伤引发的炎症性疾病的临床管理。
